While our study focuses on relatively early administration of STING agonists (day 3 and day 7 post tumor-inoculation), the protective effects persist on bone cancer pain, bone destruction, and local tumor burden persist until relatively late time points. This evidence concerns the gene STING1 and bone cancer.